Business Wire

ITEN

21.11.2023 07:24:28 CET | Business Wire | Press release

Share
ITEN Named as CES 2024 Best of Innovation Awards Honoree

I-TEN,SA today announced that it has been named a CES® 2024 Best of Innovation Awards Honoree for its 250µA.h micro-battery This year’s CES Innovation Awards program received a record number of over 3000 submissions. The announcement was made ahead of CES 2024, the world’s most powerful technology event, happening Jan. 9-12 in Las Vegas, NV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120706085/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Solid-state SMD Micro-battery (Photo: I-TEN SA)

The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in 29 consumer technology product categories. Those with the highest rating receive the “Best of Innovation” distinction. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design.

ITEN are a French company manufacturing solid-state SMD micro-batteries. As a fully integrated device manufacturer, ITEN control the complete value chain from material synthesis up to the packaging and test. ITEN have raised more than 120M$ since the foundation of the company and their technology has been granted more than 300 patents worldwide so far.

The new 250µA.h micro-batteries have a footprint of #4,5 x 3,2 mm and have two more main features:
- they can be recharged quickly (80% in 8 minutes) and simply at constant voltage (like a capacitor);
- they can deliver high power and high peak currents, of more than 30mA over 100ms, meaning a C-Rate of more than 120.

The C-rate is a key performance for batteries used in low power IOT solutions. Such low-power IOT solutions do indeed consume less and less energy on the average but from time-to-time, the power supply must deliver current spikes to power RF transceivers, microcontrollers sensors or actuators for instance.

Thanks to the high C-rates of ITEN’s batteries, it is now possible to reduce the size and the capacity (by a factor up to 500 or 1000) of the batteries to be used in such IOT solutions: This also reduces the carbon footprint of the energy storage solutions by a factor at least 200 compared to coin cells and this even makes it possible to design ecofriendly autonomous solutions by combining energy harvesting solutions and a micro-battery of very small capacity. In addition, ITEN micro-batteries are ROHS and REACH compliant and contain neither toxic materials, nor heavy metals, nor solvents, no rare earths and do not require a specific recycling process at the end of the system life.

They are thus a concrete response to electronics designers looking for ecofriendly alternatives to coin cells. In this respect, ITEN solutions fit in with the European Directive recommending getting rid of non-rechargeable batteries in all electronic system designs from year 2030.

“We are thrilled and honored by this Best of Innovation Award at CES 2024. This recognizes our disruptive solid-state batteries as main contributors to sustainability, eco-design and smart energy solutions” stated Fabien Gaben, Chairman of the board and founder of the company. “This is really a breakthrough in the way of powering autonomous embedded systems.”

The CES 2024 Innovation Awards honorees, can be found at CES.tech/innovation. More will be revealed in January during CES Unveiled.

About ITEN:
ITEN is the leading company developing and manufacturing ecofriendly solid-state lithium-ion SMD micro batteries. Such micro batteries are rechargeable In a few minutes and can deliver power over a wide operating temperature range. They are used in many applications as back-up power supply, or to assist primary cells in delivering power or to power autonomous sensor nodes, tracking and monitoring solutions, sensor data loggers, beacons and RF tags, smartphone peripherals, medical devices, home and building automation, smart cities, wearables, and e-textiles.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120706085/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release

Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa

ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release

ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document

SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release

Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as

Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release

Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release

-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye